<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04309422</url>
  </required_header>
  <id_info>
    <org_study_id>RECHMPL19_0623</org_study_id>
    <nct_id>NCT04309422</nct_id>
  </id_info>
  <brief_title>Texture Features and PDL1 in CT-PET 18 FDG</brief_title>
  <official_title>Correlation Between Texture Features With CT-PET 18 FDG and Overexpression of PDL1 in Non-small-cell Lung Carcinomas During the Initial Staging.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Search correlation between texture features in CT-PET 18 FDG and overexpression of PDL1 in
      non-small cell lung carcinomas during the inital staging.

      The hypothesis is that overexpression of PDL1is correlated with at least one texture feature
      among those selected.

      84 CT-PET 18 FDG at the initial staging of a non small cell lung carcinoma (adenocarcinoma or
      squamous cell carcinoma), whose the biopsed site was the primitive site or the drainage
      lymphadenopathy, without previous treatment, were recruited and analyzed by a software
      allowing to estimate texture features.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 1, 2018</start_date>
  <completion_date type="Actual">January 31, 2020</completion_date>
  <primary_completion_date type="Actual">October 1, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation between at least one texture feature and overexpression of PDL1</measure>
    <time_frame>1 day</time_frame>
    <description>Correlation between at least one texture feature and overexpression of PDL1</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">84</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Overexpression of PDL1</arm_group_label>
    <description>Overexpression of PDL1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Absence of overexpression of PDL1</arm_group_label>
    <description>Absence of overexpression of PDL1</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patient with initial CT-PET 18 FDG realized in the nuclear service of Montpellier
        university hospital, with non small cell lung carcinoma diagnosed with biopsy of the
        primitive site or local drainage lymphadenopathy.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  adult patient ;

          -  first CT-PET 18 FDG realized for the inital staging ;

          -  absence of previous treatment for a thoracic neoplasm ;

          -  biopsy realized on the primitive site or local drainage lymphadenopathy ;

          -  primitive site viewable with morphological imagery ;

          -  availability of evaluation of PDL1's overexpression ;

        Exclusion criteria

        - Refusal to participate in this research
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Baptiste MALLET</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospitals of Montpellier</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Uh Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 12, 2020</study_first_submitted>
  <study_first_submitted_qc>March 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 16, 2020</study_first_posted>
  <last_update_submitted>March 16, 2020</last_update_submitted>
  <last_update_submitted_qc>March 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Correlation between overexpression of PDL1</keyword>
  <keyword>texture features</keyword>
  <keyword>CT-PET 18 FDG</keyword>
  <keyword>Non Small Cell Lung Carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>NC</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

